ClinicalTrials.gg
CompletedNCT03080558INDIEUpdated Nov 9, 2026

Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving

A Phase 4 interventional study of Indocyanine green in Deep Endometriosis and Recto Vaginal Node, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by University Hospital, Clermont-Ferrand · Phase 4, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Enrollment
59th of 70
30 · median 91
Started
2017
with 3 others
Phase 4
Only one
of the 128
Registered
21st of 128
by date
Lead sponsor
6 of 128
University Hospital, Clermont-Ferrand

Among the 128 studies in Endometriosis with a site in France, this one is the 59th largest by enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2017, is the only one in phase 4, and was the 21st registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

Indocyanine green is a dye, using in surgery to bring out the intraoperative evaluation of tissue perfusion.

After intravenous injection of indocyanine green, using a near infrared light, the vascularisation becomes fluorescent.

In endometriosis disease, the treatment of recto vaginal node can be complicated by rectovaginal fistula.

An abnormal vascularisation related to the surgery would be a risk factor of post operative fistulas.

The aim of this study is to evaluate the rectal and vaginal vascularisation during the treatment of a recto vaginal endometriosis nodule with rectal shaving, using indocyanine green fluorescence.

Read the detailed description

Investigators are going to inject, at the end of a rectal shaving, a bolus of 0,2mg/kg of indocyanine green after dilution (2,5mg/ml). With de SPIES system (KARL STORZ GmbH \& Co. KG, Tuttlingen, Germany), the vascularisation would be imediately fluorescent. Investigators are going to estimate the vascularization of the rectal serosa and mucosa where the nodule was located.

If a vaginal resection has been performed, investigators are going to estimate the vascularization of the vaginal scar.

To estimate de vascularization, investigators are going tu use a scale with a score between 0 and 4.

After the surgery, the post-operative follow-up with be the same as usual after a Rectal Shaving.

03

Conditions studied

  • Deep Endometriosis
  • Recto Vaginal Node

Browse trials for

Keywords

  • Indocyanine green fluorescence
  • Rectal vascularisation
  • Vaginal vascularisation
  • Laparoscopic surgery
  • Rectal shaving
  • Recto vaginal node
  • Deep Endometriosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients above the age of 18 year
  • Patients with endometriosis recto vaginal node
  • Patients with operative indications of rectal shaving, with or without vaginal resection
  • Patients who have accepted to participate

Exclusion criteria

Exclusion Criteria:

  • minors patients
  • Patients under guardianship or wardship
  • Patients who refused the participation
  • Iodine allergy
  • Pregnant woman
  • Patients during lactation
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    endometriosis recto vaginal node

    Drug: Indocyanine green

Interventions

06

What researchers measure

Primary outcomes

  1. Per-operative evaluation of the rectum

    Per-operative evaluation of the rectum after Shaving, using indocyanine green fluorescence, by transperitoneal and intra-rectal approach, and vaginal suture if there is an associated vaginal resection. A fluorescence score between 0 and 4 will be used, based on a Likert scale

    Time frame: at day 1

Secondary outcomes

  1. Side effects after indocyanine green injection

    Time frame: at day 1

  2. Post operative complications

    infections, abdominal abscess, abdominal hematoma, post operative fistula.

    Time frame: at day 1

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Bourdel N, Jaillet L, Bar-Shavit Y, Comptour A, Pereira B, Canis M, Chauvet P. Indocyanine green in deep infiltrating endometriosis: a preliminary feasibility study to examine vascularization after rectal shaving. Fertil Steril. 2020 Aug;114(2):367-373. doi: 10.1016/j.fertnstert.2020.03.042. Epub 2020 Jul 7. PubMed 32646588 ↗
  • Bar-Shavit Y, Jaillet L, Chauvet P, Canis M, Bourdel N. Use of indocyanine green in endometriosis surgery. Fertil Steril. 2018 Jun;109(6):1136-1137. doi: 10.1016/j.fertnstert.2018.02.113. Epub 2018 Jun 6. PubMed 29885885 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Aug 2017 to primary completion in Oct 2020, 37 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Feb 2019 → Oct 2020 and completion Feb 2019 → Nov 2020.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2017
First posted
Mar 15, 2017
StartActual
Aug 6, 2017
Primary completionActual
Oct 4, 2020was Feb 2019
CompletionActual
Nov 4, 2020was Feb 2019
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 9, 2026
Primary completion
Feb 28, 2019→Oct 4, 2020 (actual)
Nov 9, 2026
Study completion
Feb 28, 2019→Nov 4, 2020 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Status unknown→Completed
    Primary completion Feb 28, 2019→Oct 4, 2020 (now actual)
    Study completion Feb 28, 2019→Nov 4, 2020 (now actual)
    + 4 other changes: identifiers, contact details, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03080558
Collaborators
Laboratoire SERB, Association GEGO
Responsible party
Sponsor
First posted
Mar 15, 2017
Start date
Aug 6, 2017
Primary completion
Oct 4, 2020
Completion
Nov 4, 2020
Last update
Nov 9, 2026

Study contacts

Nicolas BOURDEL
principal investigator · University Hospital, Clermont-Ferrand

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indocyanine Green

Start the discussion